布地奈德入医保了吗？

(Budesonide, Budenofalk) Is it covered by medical insurance? Let's take a look. Budesonide (Budenofalk) is a medical insurance drug. Budesonide (Budenofalk) is included in Class B medical insurance in the "Basic Medical Insurance Drug Catalog" and can be reimbursed by medical insurance. However, reimbursement ratios vary from place to place. For specific reimbursement information, patients can consult the local medical insurance bureau.

Budesonide (Budenofalk) is a glucocorticoid with highly effective local anti-inflammatory effects. It can enhance the stability of endothelial cells, smooth muscle cells and lysosomal membranes, inhibit immune responses and reduce antibody synthesis, thereby reducing the release and activity of allergic active mediators such as histamine. It can also reduce the enzymatic process triggered when antigens and antibodies are combined, inhibit the synthesis and release of bronchoconstrictive substances and reduce the contractile response of smooth muscles. Acute, subacute and long-term toxicity studies have found that the systemic effects of budesonide, such as weight loss, lymphoid tissue and adrenal cortex atrophy, are weaker than or equivalent to other glucocorticoids. After systematic evaluation in six different experimental tests, budesonide has no mutagenic or carcinogenic effects.

Budesonide (Budenofalk) belongs to the adrenocortical hormone drugs. Budesonide (Budenofalk) is a non-halogenated glucocorticoid that has a strong local anti-inflammatory effect and can inhibit early bronchospasm and late allergic reactions. It is one of the important drugs for the treatment of allergic asthma.

The most common side effects of Budesonide (Budenofalk) include: 1. About 5% of patients will experience local irritation as an adverse reaction when using Budesonide. 2. Common adverse reactions of Budesonide: local irritation, slight bloody discharge, and nosebleeds. (Budesonide, Budenofalk) Rare side effects. Systemic: Angioedema Skin: Urticaria, rash, dermatitis, pruritus. Airways: Nasal septal perforation and mucosal ulceration. Immediate or delayed allergic reactions including urticaria, rash, dermatitis, angioedema, and pruritus have been reported. A rare number of patients develop mucosal ulceration and septal perforation after intranasal steroid administration.